

**NeurAxon, Inc. to Present at 20th Annual Piper Jaffray Health Care Conference
December 2, 2008**

WALTHAM, Mass. November 18, 2008 – NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company's Chief Executive Officer, will present at the 20th Annual Piper Jaffray Health Care Conference taking place December 2-3, 2008 in New York, NY.

The NeurAxon presentation will be delivered on Tuesday, December 2, 2008 at 1:50pm Eastern Time at the New York Palace Hotel.

Dr. Bloch will provide an overview of NeurAxon and its portfolio of novel, proprietary pain therapeutics, including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in development for migraine with aura.

About NeurAxon Inc.

NeurAxon Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

Contact:

Chris Erdman
MacDougall Biomedical Communications
781-235-3060, ext. 14